Subscribe
shutterstock_1169341219
Grand Warszawski / Shutterstock.com
25 February 2019Americas

Roche to make $4.3bn gene therapy acquisition

Switzerland-based  Roche will buy gene therapy company  Spark Therapeutics in a $4.3 billion deal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.

More on this story

Americas
Catalent to buy $1.2bn gene therapy company
17 April 2019   Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
Americas
Roche buys fibrotic diseases biotech in $1.4bn deal
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent